Bromantane and derivatives: fibrosis research — WO2020191503A1
Mark Williams · 2020 · WO2020191503A1 · patent family 72609163
Published 2020-10-01.
Reported patent results
Narrative findings; numerical extraction incomplete
The renal experiment reports lower fibrosis and blood urea nitrogen with bromantane, alongside some neutral or numerical-only organ-weight comparisons.
Preclinical fibrosis/metabolic-organ experiments; the selected renal comparison uses bromantane, vehicle and telmisartan.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Kidney fibrosis and BUN | Significant reductions versus vehicle reported | Exact effect sizes and figure values were not transcribed; no patient trial |
| Kidney weight | Affected-kidney weight showed a numerical reduction; the uninjured-kidney change was described as significant | Numerical change is distinguished from statistical significance |
| Telmisartan comparator | No significant reduction in the selected BUN or fibrosis measurements | A model-specific result, not proof of clinical superiority |
Multiple diseases and analogues are proposed, but results must remain linked to the compound/model actually tested. Animal organ measures do not establish human antifibrotic efficacy.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Use. The application proposes bromantane-related compounds for lung fibrosis and other organ-disease uses.
Patent experiments and proposed indications are distinct from demonstrated human treatment effects.
- Publication
- WO2020191503A1 ↗ · 2020-10-01
- Earliest priority / filing
- 2019-03-27 / 2020-03-27
- Original applicant / assignee
- Algernon Pharmaceuticals Inc
- Indexed status
- Ceased · checked 2026-11-06
- Patent family
- 72609163 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Methods and uses of bromantane and derivatives thereof for treating lung disease, fatty liver disease, and kidney disorders
Inventors: Mark Williams.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Patent experiments and proposed indications are distinct from demonstrated human treatment effects.
- Multiple diseases and analogues are proposed, but results must remain linked to the compound/model actually tested. Animal organ measures do not establish human antifibrotic efficacy.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-72609163. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Mark Williams. Bromantane and derivatives: fibrosis research — WO2020191503A1 WO2020191503A1 · patent family 72609163 2020.
Molekul research summary: https://molekul.io/research/patent-wo2020191503a1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry